Shares of Amgen AMGN fell by more than 5% on Wednesday after it reported top-line data on two different drugs in the ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Argenx stock surged Wednesday after Amgen presented "underwhelming" results for a potential competitor to Vyvgart in an autoimmune disease.

The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.

Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in ...

As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...

Medicines the company is developing for eczema and myasthenia gravis met their objectives in Phase 3 trials. But analysts weren’t convinced they can compete with available alternatives.

Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the ...

The genetic disorder, which is fatal, affects the nervous system and other organs — IntraBio's drug Aqneursa was shown to help reduce symptoms compared to a placebo. Separately, Amgen reported success ...

Argenx Se (ARGX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Akash Tewari ...

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...

Bank of America Securities analyst Tazeen Ahmad has reiterated their bullish stance on ARGX stock, giving a Buy rating today. Tazeen ...